The factors expected to drive the growth of the high-content screening market are rising need for cost containment in pharmaceutical R&D, growth in funding for cellular research, and technological advancements in HCS solutions during the forecast period. The increasing number of contract research organizations providing HCS outsourcing services and application of HCS in personalized medicine offer significant growth opportunities in the HCS market. The rising adoption of label-free technologies and growing focus on stem cell analysis are the key trends in the HCS market.
What the Market Looks Like?
Predicted to grow at a CAGR of 10.3% during the forecast period, the global High Content Screening market is estimated to reach USD 909.0 Million by 2022. North America to account for the largest market size during the forecast period.
The HCS instruments market accounted for the largest share of HCS market primarily attributed to advances in instrumentation and automation techniques and high prices of the HCS instruments. The software segment is expected to register the highest growth during the forecast period. The growth of this market is attributed to the technological advancements in image acquisition, data analysis, and storage capabilities and the need to obtain information on changes in cell morphology through high-quality images.
On the basis of application, the high-content screening market is segmented into target identification and validation, primary and secondary screening, toxicity studies, compound profiling, and other applications such as angiogenesis, apoptosis, cell cycle and mitotic index, cell proliferation, endocytosis, protein synthesis, and stem cell differentiation. The primary and secondary screening application segment is expected to grow at highest CAGR during the forecast period. The high growth can primarily be attributed to the wide use of HCS for secondary screening purposes. Growth in the primary and secondary screening segment can also be attributed to the presence of a large number of potential drug candidates for target-specific delivery.
Download PDF Brochure @
What Drives the Market?
The growth of the global market for High Content Screening is primarily influenced by the following factors:
Geographical growth scenario of High Content Screening Market
North America is the largest market for high-content screening, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. High R&D expenditure, the presence of major pharmaceutical market players, and increasing government support are some of the factors contributing to the large share of North America in the market. However, the Asia-Pacific market is expected to register the highest growth during the forecast period owing to increased research in drug discovery, government initiatives, growing focus of multinational companies on emerging markets, and developing R&D infrastructure.
Request Sample Pages @
Leading market players and strategies adopted
The prominent players in the High Content Screening market include GE Healthcare (U.S.), Danaher Corporation (U.S.), Thermo Fisher Scientific Inc. (U.S.), PerkinElmer, Inc. (U.S.), Tecan Group (Switzerland), BioTek Instruments Inc. (U.S.), Becton, Dickinson and Company (U.S.), Bio-Rad Laboratories (U.S.), Yokogawa Electric Corporation (Japan), and Merck Millipore (U.S.).